Small Cell Lung Cancer | Meet The Professor: Optimizing the Management of Small Cell Lung Cancer — Part 1

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: Journal Club (0:00) Case: A woman in her mid 50s with extensive-stage small cell lung cancer (ES-SCLC) who had an excellent response to chemotherapy with immunotherapy (IO) and has been on maintenance IO for 2 years — Adam R Miller, MD (22:05) Case: A woman in her mid 60s with ES-SCLC who presented with superior vena cava syndrome and has a near complete remission with chemo-IO — Namrata I Peswani, MD (28:27) Case: A woman in her late 80s with metastatic SCLC possibly of adrenal origin who has an excellent response to chemo-IO — John Yang, MD (34:14) Case: A woman in her mid 70s with recurrent ES-SCLC who has prolonged disease control on topotecan/trilaciclib — Ferdy Santiago, MD (41:09) Case: A woman in her late 50s with ES-SCLC and brain metastases who responds to chemo-IO but later experiences disease progression (PD) and has toxicity with topotecan — Dr Miller (45:34) Case: A woman in her late 60s with ES-SCLC who has PD on chemo-IO but responds to lurbinectedin with only mild toxicity — Mohamed K Mohamed, MD, PhD (48:28) Case: A man in his early 70s with synchronous Stage III SCLC and Stage I non-small cell lung cancer who receives concurrent chemoradiation therapy — Daniel R Carrizosa, MD, MS (1:00:34) CME information and select publications